|
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
|
24 May, 2023 |
|
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
|
08 May, 2023 |
|
INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update
|
03 May, 2023 |
|
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
|
24 Apr, 2023 |
|
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
|
19 Apr, 2023 |
|
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
|
11 Apr, 2023 |
|
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
|
03 Apr, 2023 |
|
INmune Bio, Inc. Announces 2022 Results and Provides Business Update
|
02 Mar, 2023 |
|
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
|
21 Feb, 2023 |
|
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
|
08 Feb, 2023 |
|
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
|
25 Jan, 2023 |
